Article citationsMore>>

L. Wang, H. Chen, M. H. Pourgholami, J. Beretov, J. Hao, H. Chao, A. C. Perkins, J. H. Kearsley and L. Yong, “Anti-MUC1 Monoclonal Antibody (C595) and Docetaxel Markedly Reduce Tumor Burden and Ascites and Prolong Survival in an in Vivo Ovarian Cancer Model,” Plos One, Vol. 6, No. 9, 2011, e24405. doi:10.1371/journal.pone.0024405

has been cited by the following article:

• TITLE: Synthesis and Development of Gd3+-ALGDG2-C595 as MR Imaging Contrast Agent

  AUTHORS: Mehdi Mirzaei, Mohammadali Mohagheghi, Daryoush Shahbazi-Gahrouei

  KEYWORDS: Gd3+-ALGDG2; Mucine-1; Monoclonal Antibody C595; MR Imaging; in Vitro

  JOURNAL NAME: Journal of Biomaterials and Nanobiotechnology, Vol.4 No.1, January 17, 2013

  ABSTRACT: Magnetic Resonance imaging (MR imaging) as a powerful non-invasive modality is of high global interest for early cancer detection. The aim of this study was the synthesis of nanodendrimer and its conjugate with monoclonal antibody C595 against breast cancer cell, followed by its chelating with gadolinium for its magnetic property. First, anti-MUC-1 monoclonal antibody C595 was coupled to a biodegradable biocompatible Anionic Linear Globular Dendrimer G2 (having polyethylene glycol core and citric acid shell). Then prepared nanocomplex loaded by gadolinium to make novel agent of functional MR imaging. Anticancer effects and MR imaging parameters of the prepared nanoconjugate was investigated under in vitro conditions doing performing several studies such as evaluation of monoclonal antibody C595 binding to mucine-1 (MUC-1) cell, its purification, size of nanoconjugate and relaxivity measurements. The obtained data showed a powerful relaxations as well as selective MUC-1 antigen binding to the cell. Based on the findings from the present research Gd3+-ALGDG2-C595 nano-probe may be a potential breast molecular imaging and therapeutic agent. However, further investigations by in vivo studies and clinical trials are in the pipeline.